Objective: To describe the current status of breast, colorectal and cervical cancer screening in Spain. Methodology: The situation was analysed on the basis of data drawn from surveys conducted in each autonomous region (Comunidad Auto´noma).
introduction
Cancer constitutes one of the major health problems in the developed world. In absolute terms, it is the leading cause of mortality in Spain, accounting for >25% of all deaths. The most frequent tumour sites are as follows: among men, lung, colon and rectum, and prostate [1, 2] ; and among women, breast followed by colon and rectum. Cervical cancer accounts for only 3% of all tumours diagnosed.
As a secondary prevention activity, screening is a method that has shown itself to be effective in improving prognosis of a relevant number of patients in certain types of cancer. As far back as 2003, the European Union recommended that population-based breast, cervical and colorectal cancer screening be undertaken [3] , and established the basic action criteria to guarantee quality and results in health terms. Since then, practically all European countries have implemented screening programmes, albeit with different organisational models [4] . In Spain, the 2009 National Health System (NHS) Cancer Strategy also recommends that such screening be conducted and lays down the minimum criteria for its implementation and development [5] .
The organisation of Spain's NHS is decentralised, with responsibility being delegated to the regional health systems of the country's 17 autonomous regions (ARs) (Comunidades Autónomas) and the autonomous cities (Ciudades Autónomas) of Ceuta and Melilla [6] , each of which is responsible for local application of these programmes. This type of territorial organisation, with widely decentralised powers, has led to differing application of cancer screening policies in the various ARs. Nevertheless, 20 years ago, coinciding with the commencement in Spain of the first breast cancer screening programmes, a network was set up. This is the 'Network of Spanish Cancer Screening Programmes' (Red de Programas Españoles de Cribado de Cáncer) (initially covering breast cancer), which, in addition to sharing information and experience in this field, has allowed for inter-regional co-ordination aimed at reaching agreement on the basic criteria for implementation and development of the respective screening programmes, as well as defining the indicators that would, as far as possible, enable joint evaluation [7] . One example of this type of evaluation is the 'DESCRIC Report' [8] , drawn up in 2006 for the purpose of describing at that time the status of screening in Spain and updating the pertinent scientific evidence.
This article describes the current status of implementation of the different screening programmes in Spain in respect of the three cancers for which screening is clearly recommended, namely, breast, colorectal and cervical, and the differences arising from the Spanish health system's decentralised organisation. Coverage indicators and, as far as possible, the results of the activities undertaken are analysed for each type of cancer.
subjects and methods
The organisation and development of the respective screening programmes is independent. Consequently, the methodology used for data collection and analysis was different for each tumour type, although the health structure of the ARs means that in many cases these come under the same departments and the same heath officials and managers.
breast cancer
The data shown here were drawn from the annual survey conducted by the Network of Spanish Cancer Screening Programmes for the purpose of updating information on the characteristics of each programme. Simultaneously, data on annual activity were collected in a structured manner so as to assess these programmes overall. This study analysed data for 2007, the last year for which final information was available.
Indicators were calculated as per the definitions laid down in the European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis [9] . The results obtained were compared with the reference values established in the above-mentioned guidelines.
A total of 16 of the 19 ARs responded to the questionnaire, so that we had information corresponding to almost 90% of the activity undertaken (Table 1 ). In the case of one AR, there were no data on the age of the women examined (21 899 examinations, 1.7% of the total). Data broken down by type of examination were obtained for nine ARs, which accounted for 60% of the examinations (75% of initial examinations).
colorectal cancer
With respect to colorectal cancer screening, these programmes form part of the Network of Spanish Cancer Screening Programmes. Applying similar criteria to those described above, a first questionnaire was drawn up which gathered data on programme characteristics, i.e. year of introduction, target population, methodology, quality-control systems, etc. We agreed on assessment indicators, such as participation, positive test, invasive cancer and neoplastic lesion detection rates, and rate of advanced cancers, which would be analysed jointly for all programmes, in line with the criteria stipulated by the European Cancer Network group of experts in the quality guideline currently being drawn up.
This study describes the current status of this type of screening and analyses the data on the results of programmes that had concluded a minimum of a first round.
cervical cancer
Almost all cervical cancer screening activity is undertaken opportunistically. Data on the status of the programmes and a description of the criteria upon which this activity is implemented were obtained by means of a questionnaire sent to the heath officials and managers of each AR [8] . To ascertain coverage, including both public and private health systems, data from two surveys were analysed. These were the 2006 National Health Survey (Encuesta Nacional de Salud) [10] and a study which in 2005 evaluated practice and factors linked to cervical cancer screening in Spain, based on a survey of 6852 women aged 18-70 years drawn from 17 ARs (AFRODITA Study) [11] .
results

breast cancer screening
Currently, Spain's 17 ARs and 2 autonomous cities all have population-based breast cancer screening programmes. Navarre was the first to implement its programme, with this being initiated in 1990, and was progressively followed by the remaining ARs. All these programmes have already attained 100% coverage. For each region Table 1 describes the number of women invited along with some relevant results. All the programmes included women aged 50-64 years in their target population: three started at age 45 years and, though they all began by having an upper age limit of 65 years, at the time of writing all had raised or were in the process of raising this to age 69 years ( Table 2 ). In general, all women were personally invited every 2 years. In all cases, two mammographic projections were made during both the initial and-except in one programme-successive rounds. The classification used for mammogram reading was the Bi-Rads (or compatible) classification, and all regions used the physical quality control protocols established in the European Guidelines.
participation. Mean overall participation was 67.0%. On the whole, analysis by age group displayed no significant differences, though the trend was upward. Participation of women invited to the programmes for the first time was 63.8%, and showed a clear downward trend with age (Table 3) .
Insofar as programme adherence was concerned, 91.2% (86%-97% depending on the AR) of all women who participated in the previous round, took part in the current round, thus indicating the acceptability of the programmes once a woman has joined them. As in the case of participation, there were no significant differences by age group.
cancer detection rates and characteristics of diagnosed tumours. The overall detection rate was 3.4& of explored women, showing a growing trend with age for both initial and subsequent examinations, with the rate in all cases being higher in the first group.
With respect to type of tumour diagnosed, no data could be obtained in 12% of cases. Of the remainder, 15.1% were intraductal, with a slight difference between the two subgroups of women analysed. Almost 30% of invasive cancers were a maximum of 1 cm in diameter. A significantly lower percentage was observed among the initial group of women (20.8%) compared with successive groups (28.9%), though in both cases these percentages were close to the desirable reference values of 25% and 30%, respectively. In all, only 22.4% of invasive tumours exceeded 2 cm in diameter. In this case, the difference between women who were examined for the first time and those who had been previously examined was not quite as marked.
A little over 65% of tumours detected showed no ganglion infiltration. No difference was observed according to type of examination performed.
colorectal cancer screening
In line with European Council and NHS Cancer Strategy recommendations, as a target of their health and/or oncological health plans Spain's ARs have been incorporating a commitment to conducting pilot studies for the implementation of population-based screening programmes and the development of strategies for care of high-risk individuals and families. Related scientific societies have made recommendations and drawn up clinical practice guidelines, insisting on the need for these types of programme to be implemented [12] .
In 2007, consensus meetings were held to establish the methodology and information systems on which such programmes should be based, in order to ensure their quality and continuity [13] .
first-round coverage and results. Of Spain's 17 ARs, six have initiated screening programmes, i.e. Catalonia, Valencian Region, Murcia, Basque Country, Cantabria and the Canary Islands, representing 40% of the Spanish population ( Table 4) . The remainder have undertaken to initiate this activity progressively in the short term.
The programmes currently in operation include men and women aged 50-69 years as their target population (except Cantabria which starts at age 55 years). In 2009, 418 973 persons were included in a screening programme (4.5% of the Spanish population in this age group, 9500 000 persons), and by 2014 minimum coverage is estimated to be 50%.
The test used was the faecal occult blood est (FOBT), based on guaiac resin in the first round in Catalonia and Valencia, and on immunoassay in Murcia and the Basque Country. In subsequent rounds, the immunological test was also incorporated into the Catalonian and Valencian programmes. As far as periodicity was concerned, in all cases tests were repeated every 2 years.
The first-round results of pilot studies in four regions were available (Catalonia since 2000 [14] (Table 5 ). Participation ranged from 17.2% to 59.0% (Catalonia attained a secondround figure of 22%). The positive test percentage ranged from 1.7% to 9.5%, with an invasive cancer detection rate of 1.7& to 3.4&.
cervical cancer screening
In Spain, all ARs currently had cervical cancer screening programmes (Table 6 ), though these were mostly of the opportunistic type, except in La Rioja where the programme was population based (direct invitation by mail) and in Castile and Leó n where, despite there being no direct appointment system, a protocolised awareness-raising campaign was directed at the target population so that they would seek screening. Some ARs were debating whether to complete the opportunistic strategy by implementing pilot projects that included other capture strategies. The scope of performance of the test was delimited to primary and specialised care, and family planning.
Programmes varied in terms of starting age and screening interval, reflecting the lack of consensus among scientific societies, though in the NHS Cancer Strategy a recommendation is made in this regard. There was a predominance of protocols that included women aged 25-65 years, with a periodicity of 3-5 years.
In terms of technique, the Papanicolau smear (Pap smear) was used in all ARs, in some cases with liquid-based cytology. Determination of the papilloma virus was used in some programmes for specific situations (cytologies of unknown significance, women with inadequate previous screening or at-risk populations).
screening coverage. The percentage of women effectively covered by the screening test in the target population was relatively high. In the 2006 National Health Survey [9] , 69.0% of women aged >20 years reported having undergone cytology at least once, with percentages that ranged from 55% to 80% depending on the AR. In nine of the ARs studied, accounting for 54.2% of the Spanish population, this percentage ranged from 60% to 70%. In five of these (37.9% of the total population), this stood at 70%-80%, with the 80% mark being surpassed in only one (4.5% of the population). Overall coverage proved highest in the 45-to 54-year group (86.3%), and decreased in the younger and older groups (Figure 1 ). With respect to the screening interval, most women reported an annual periodicity in the performance of cytology, across all age groups (Table 7) . The results of the AFRODITA Study [11] reveal higher coverage figures. According to this study, 86% of women reported having undergone cytology at some time in their lives, 42% in the preceding year, 69% in the preceding 3 years and 75% in the preceding 5 years. The data indicated lower coverages among women who were older, had a low socioeconomic level and came from rural areas. These figures ranged from 85.9% of women who had undergone at least one cytology in the preceding 3 years in the Canary Islands to 61.3% in Extremadura.
discussion
Cancer screening has been proposed as an effective control method for certain types of cancer and in this respect has been recommended by numerous scientific organisations and societies. Europe is a model for implementation of organised population-based programmes and, in our case, the drawingup of European quality guidelines for breast cancer, cervical and, in the near future, colorectal cancer screening programmes, has been instrumental in the development of screening programmes in this country. This fact has been extremely relevant in discussions held at the screening programme network and has enabled consensus to be reached on indicators, quality criteria and assessment of regional programmes. As a result, one can now speak of a reasonably uniform screening programme in Spain for breast cancer, and probably for colorectal cancer as well. Likewise, existing initial differences have been reduced. Of equal note is the convergence, in terms of consideration being given exclusively to an opportunistic cervical cancer screening strategy, which is in evidence in all regions and is reflected in the NHS Cancer Strategy.
Since 1990, the year in which the first population-based breast cancer screening programme was implemented in Spain, the interest and priority devoted to its implementation and development have, in part, been endorsed by all health authorities, national and regional. Breast cancer screening programmes in Spain have already attained 100% coverage. Special mention should be made of the notable acceptability of screening mammography as part of organised programmes, as is shown by the overall participation and high degree of adherence.
Given the variability in implementation of programmes and the time elapsed since many of them were started, an accurate estimate of expected overall incidence in Spain could not be made but, judging by the partial results, the detection rate can be estimated to lie within the expected range. The types of tumour detected are consistent with the diagnostic in advance that these programmes yield. The various indicators-in the majority of cases in line with the recommendations established by the European guidelines and, moreover, similar to those in other countries [15] -suggest that mortality in Spain will decline significantly, as is indicated by the fact that this is already taking place in the regions where these programmes were originally introduced [16] . The situation with respect to colorectal screening is somewhat different. Compared with the extent of its deployment in other European countries, implementation of this type of screening is extremely limited in Spain [4] . Only six ARs are developing pilot programmes in the initial stages, though most of the remainder envisage initiating similar projects in 1 or 2 years' time. It is envisaged that colorectal screening will be extended to at least 50% of the target population within a period of 5 years. The time of implementation will enable it to be extended, using the lessons learnt from the experience of implementing and developing breast cancer screening programmes. Indeed, the fact that from the outset a network of existing programmes is in place is a step in this direction.
The participation obtained in the programmes undertaken in Spain shows great variability and is below that obtained in other programmes in Europe, e.g. 56.8% in the UK [17] and 44.6% in Italy [18] . Informing the public as to the importance of this health problem and the possibilities of prevention and early diagnosis is crucial to enhancing the effectiveness of such actions.
Insofar as the percentage of positive tests is concerned, the differences can be attributed to the test used (guaiac or immunological), since these same differences are observed in other European programmes when different tests are also used [17, 18] . The same can be concluded with regard to the invasive cancer detection rate. The principal argument used for applying cervical cancer screening with an opportunist strategy is the low frequency of this tumour in this country. Organised programmes have shown that both incidence and mortality are reduced: albeit to a lesser degree, opportunistic programmes also manage to reduce these rates [19, 20] , though this type of strategy may entail inequalities of access.
The information furnished by cross-sectional studies and Spanish health surveys indicates that opportunistic screening coverages are high, though there is a difference of 17 percentage points between the two sources used [10, 11] .
This difference may be linked to the different characteristics of the respective surveys, since, unlike the AFRODITA study in which this aspect was investigated to the exclusion of all others, the fact that many other health-related aspects are included in the National Health Survey might lead to a lower recall effort in specific responses on cervical screening. The data suggest, moreover, that whereas many women undergo cytology more frequently than is recommended, there are groups of women among whom coverage must nevertheless be improved (older women, rural areas and less privileged social levels).
In view of this situation and the absence of population-based programmes, most of Spain faces the challenge of boosting opportunistic screening in an attempt to attain the following two fundamental goals: on the one hand, to improve coverage, particularly in the above-mentioned subgroups, so as to reduce inequalities of accessibility; and, on the other, to standardise criteria, in terms of both starting age and screening interval, so as to prevent many women from undergoing cytology more frequently than is recommended. Finally, a specific effort should be made by health authorities to assure screening test quality, which, in an opportunistic context, is something that merits special attention.
In conclusion, cancer screening practice in Spain is being performed in accordance with the pertinent national and international recommendations. Despite the decentralisation of health competencies in the respective regional health systems, the fact that screening programmes are operated as a network has led to a high degree of consensus on methodology and information systems, which in turn allows for joint evaluation and comparison of results. 
